Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.
Identifieur interne : 008840 ( Main/Exploration ); précédent : 008839; suivant : 008841Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.
Auteurs : Madsen Beau De Rochars [Haïti] ; Abdel N. Direny ; Jacquelin M. Roberts ; David G. Addiss ; Jeanne Radday ; Michael J. Beach ; Thomas G. Streit ; Desire Dardith ; Jack Guy Lafontant ; Patrick J. LammieSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2004.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (administration et posologie), Albendazole (usage thérapeutique), Animaux, Antihelminthiques (administration et posologie), Antihelminthiques (usage thérapeutique), Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Fèces (parasitologie), Humains, Mâle, Nematoda (), Nourrisson, Nouveau-né, Parasitoses intestinales (), Parasitoses intestinales (parasitologie), Parasitoses intestinales (traitement médicamenteux), Parasitoses intestinales (épidémiologie), Prévalence, Répartition par âge, Surveillance sentinelle.
- MESH :
- administration et posologie : Albendazole, Antihelminthiques, Diéthylcarbamazine.
- parasitologie : Fèces, Parasitoses intestinales.
- traitement médicamenteux : Filariose lymphatique, Parasitoses intestinales.
- usage thérapeutique : Albendazole, Antihelminthiques, Diéthylcarbamazine.
- épidémiologie : Filariose lymphatique, Parasitoses intestinales.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique, Humains, Mâle, Nematoda, Nourrisson, Nouveau-né, Parasitoses intestinales, Prévalence, Répartition par âge, Surveillance sentinelle.
English descriptors
- KwdEn :
- Adolescent, Adult, Age Distribution, Albendazole (administration & dosage), Albendazole (therapeutic use), Animals, Anthelmintics (administration & dosage), Anthelmintics (therapeutic use), Child, Child, Preschool, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Feces (parasitology), Female, Humans, Infant, Infant, Newborn, Intestinal Diseases, Parasitic (drug therapy), Intestinal Diseases, Parasitic (epidemiology), Intestinal Diseases, Parasitic (parasitology), Intestinal Diseases, Parasitic (prevention & control), Male, Middle Aged, Nematoda (drug effects), Prevalence, Sentinel Surveillance.
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics, Diethylcarbamazine.
- chemical , therapeutic use : Albendazole, Anthelmintics, Diethylcarbamazine.
- drug effects : Nematoda.
- drug therapy : Elephantiasis, Filarial, Intestinal Diseases, Parasitic.
- epidemiology : Elephantiasis, Filarial, Intestinal Diseases, Parasitic.
- parasitology : Feces, Intestinal Diseases, Parasitic.
- prevention & control : Elephantiasis, Filarial, Intestinal Diseases, Parasitic.
- Adolescent, Adult, Age Distribution, Animals, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Prevalence, Sentinel Surveillance.
Abstract
Annual mass treatment with antifilarial drugs is the cornerstone of the global program to eliminate lymphatic filariasis (LF). Although the primary goal of the program is to interrupt transmission of LF, additional public health benefits also are expected because of the known anthelminthic properties of these drugs. Since rapid re-infection with intestinal helminths occurs following treatment, annual de-worming may not be sufficient to produce a lasting reduction in the prevalence and intensity of these infections. We conducted stool examinations in four sentinel communities before and approximately nine months after each of two rounds of mass drug administration (MDA) with diethylcarbamazine and albendazole in the context of an LF elimination program in Leogane, Haiti. At baseline, overall Ascaris, Trichuris, and hookworm infection prevalences were 20.9%, 34.0%, and 11.2%, respectively (n = 2,716 stools). Nine months after the second MDA, Ascaris, Trichuris and hookworm prevalences had decreased significantly, to 14.1%, 14.6%, and 2.0%, respectively (n = 814 stools). Infection intensity decreased significantly for all three parasites as well. These results demonstrate that substantial reductions in intestinal helminth infections are associated with mass treatment of filariasis in Haiti and are consistent with the conclusion that high levels of coverage for the LF program can decrease transmission of geohelminths.
PubMed: 15516644
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003E68
- to stream PubMed, to step Curation: 003E68
- to stream PubMed, to step Checkpoint: 003E68
- to stream Ncbi, to step Merge: 001B95
- to stream Ncbi, to step Curation: 001B95
- to stream Ncbi, to step Checkpoint: 001B95
- to stream Main, to step Merge: 008B00
- to stream Main, to step Curation: 008840
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.</title><author><name sortKey="De Rochars, Madsen Beau" sort="De Rochars, Madsen Beau" uniqKey="De Rochars M" first="Madsen Beau" last="De Rochars">Madsen Beau De Rochars</name><affiliation wicri:level="1"><nlm:affiliation>Hopital Ste. Croix, Leogane, Haiti. mbeauder@nd.edu</nlm:affiliation><country xml:lang="fr">Haïti</country><wicri:regionArea>Hopital Ste. Croix, Leogane</wicri:regionArea><wicri:noRegion>Leogane</wicri:noRegion></affiliation></author><author><name sortKey="Direny, Abdel N" sort="Direny, Abdel N" uniqKey="Direny A" first="Abdel N" last="Direny">Abdel N. Direny</name></author><author><name sortKey="Roberts, Jacquelin M" sort="Roberts, Jacquelin M" uniqKey="Roberts J" first="Jacquelin M" last="Roberts">Jacquelin M. Roberts</name></author><author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name></author><author><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name></author><author><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name></author><author><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></author><author><name sortKey="Dardith, Desire" sort="Dardith, Desire" uniqKey="Dardith D" first="Desire" last="Dardith">Desire Dardith</name></author><author><name sortKey="Lafontant, Jack Guy" sort="Lafontant, Jack Guy" uniqKey="Lafontant J" first="Jack Guy" last="Lafontant">Jack Guy Lafontant</name></author><author><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15516644</idno><idno type="pmid">15516644</idno><idno type="wicri:Area/PubMed/Corpus">003E68</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003E68</idno><idno type="wicri:Area/PubMed/Curation">003E68</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003E68</idno><idno type="wicri:Area/PubMed/Checkpoint">003E68</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003E68</idno><idno type="wicri:Area/Ncbi/Merge">001B95</idno><idno type="wicri:Area/Ncbi/Curation">001B95</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B95</idno><idno type="wicri:doubleKey">0002-9637:2004:De Rochars M:community:wide:reduction</idno><idno type="wicri:Area/Main/Merge">008B00</idno><idno type="wicri:Area/Main/Curation">008840</idno><idno type="wicri:Area/Main/Exploration">008840</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.</title><author><name sortKey="De Rochars, Madsen Beau" sort="De Rochars, Madsen Beau" uniqKey="De Rochars M" first="Madsen Beau" last="De Rochars">Madsen Beau De Rochars</name><affiliation wicri:level="1"><nlm:affiliation>Hopital Ste. Croix, Leogane, Haiti. mbeauder@nd.edu</nlm:affiliation><country xml:lang="fr">Haïti</country><wicri:regionArea>Hopital Ste. Croix, Leogane</wicri:regionArea><wicri:noRegion>Leogane</wicri:noRegion></affiliation></author><author><name sortKey="Direny, Abdel N" sort="Direny, Abdel N" uniqKey="Direny A" first="Abdel N" last="Direny">Abdel N. Direny</name></author><author><name sortKey="Roberts, Jacquelin M" sort="Roberts, Jacquelin M" uniqKey="Roberts J" first="Jacquelin M" last="Roberts">Jacquelin M. Roberts</name></author><author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name></author><author><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name></author><author><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name></author><author><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></author><author><name sortKey="Dardith, Desire" sort="Dardith, Desire" uniqKey="Dardith D" first="Desire" last="Dardith">Desire Dardith</name></author><author><name sortKey="Lafontant, Jack Guy" sort="Lafontant, Jack Guy" uniqKey="Lafontant J" first="Jack Guy" last="Lafontant">Jack Guy Lafontant</name></author><author><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Distribution</term><term>Albendazole (administration & dosage)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Anthelmintics (administration & dosage)</term><term>Anthelmintics (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Feces (parasitology)</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Intestinal Diseases, Parasitic (drug therapy)</term><term>Intestinal Diseases, Parasitic (epidemiology)</term><term>Intestinal Diseases, Parasitic (parasitology)</term><term>Intestinal Diseases, Parasitic (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Nematoda (drug effects)</term><term>Prevalence</term><term>Sentinel Surveillance</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (administration et posologie)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Antihelminthiques (administration et posologie)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Fèces (parasitologie)</term><term>Humains</term><term>Mâle</term><term>Nematoda ()</term><term>Nourrisson</term><term>Nouveau-né</term><term>Parasitoses intestinales ()</term><term>Parasitoses intestinales (parasitologie)</term><term>Parasitoses intestinales (traitement médicamenteux)</term><term>Parasitoses intestinales (épidémiologie)</term><term>Prévalence</term><term>Répartition par âge</term><term>Surveillance sentinelle</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Nematoda</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Intestinal Diseases, Parasitic</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Intestinal Diseases, Parasitic</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Fèces</term><term>Parasitoses intestinales</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Feces</term><term>Intestinal Diseases, Parasitic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Intestinal Diseases, Parasitic</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Parasitoses intestinales</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Parasitoses intestinales</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Distribution</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Sentinel Surveillance</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Mâle</term><term>Nematoda</term><term>Nourrisson</term><term>Nouveau-né</term><term>Parasitoses intestinales</term><term>Prévalence</term><term>Répartition par âge</term><term>Surveillance sentinelle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Annual mass treatment with antifilarial drugs is the cornerstone of the global program to eliminate lymphatic filariasis (LF). Although the primary goal of the program is to interrupt transmission of LF, additional public health benefits also are expected because of the known anthelminthic properties of these drugs. Since rapid re-infection with intestinal helminths occurs following treatment, annual de-worming may not be sufficient to produce a lasting reduction in the prevalence and intensity of these infections. We conducted stool examinations in four sentinel communities before and approximately nine months after each of two rounds of mass drug administration (MDA) with diethylcarbamazine and albendazole in the context of an LF elimination program in Leogane, Haiti. At baseline, overall Ascaris, Trichuris, and hookworm infection prevalences were 20.9%, 34.0%, and 11.2%, respectively (n = 2,716 stools). Nine months after the second MDA, Ascaris, Trichuris and hookworm prevalences had decreased significantly, to 14.1%, 14.6%, and 2.0%, respectively (n = 814 stools). Infection intensity decreased significantly for all three parasites as well. These results demonstrate that substantial reductions in intestinal helminth infections are associated with mass treatment of filariasis in Haiti and are consistent with the conclusion that high levels of coverage for the LF program can decrease transmission of geohelminths.</div></front></TEI><affiliations><list><country><li>Haïti</li></country></list><tree><noCountry><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name><name sortKey="Dardith, Desire" sort="Dardith, Desire" uniqKey="Dardith D" first="Desire" last="Dardith">Desire Dardith</name><name sortKey="Direny, Abdel N" sort="Direny, Abdel N" uniqKey="Direny A" first="Abdel N" last="Direny">Abdel N. Direny</name><name sortKey="Lafontant, Jack Guy" sort="Lafontant, Jack Guy" uniqKey="Lafontant J" first="Jack Guy" last="Lafontant">Jack Guy Lafontant</name><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name><name sortKey="Roberts, Jacquelin M" sort="Roberts, Jacquelin M" uniqKey="Roberts J" first="Jacquelin M" last="Roberts">Jacquelin M. Roberts</name><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></noCountry><country name="Haïti"><noRegion><name sortKey="De Rochars, Madsen Beau" sort="De Rochars, Madsen Beau" uniqKey="De Rochars M" first="Madsen Beau" last="De Rochars">Madsen Beau De Rochars</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008840 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008840 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15516644
|texte= Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15516644" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |